This randomized controlled trial of acetaminophen in severe malaria shows that acetaminophen reduces kidney dysfunction and risk of developing AKI, particularly in patients presenting with high plasma hemoglobin, supporting the hypothesis that acetaminophen inhibits cell-free hemoglobin-mediated renal tubular oxidative damage.